Trial Profile
A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A B C Y W-135 conjugate (Primary)
- Indications Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
- Focus Therapeutic Use
- Sponsors Novartis Vaccines
- 27 Jul 2018 Results from NCT02140762 and its extension NCT02285777 studies published in the Vaccine
- 21 Jul 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
- 31 Mar 2015 Planned End Date changed from 1 May 2015 to 1 Jun 2015, according to to ClinicalTrials.gov record.